News
09-29-2009, 11:20 AM
BERLIN - The potent oral multiple kinase inhibitor sorafenib (NexavarR) combined with the chemotherapy drug capecitabine (XelodaR) significantly improves progression-free survival (PFS) over capecitabine alone in patients with locally advanced or metastatic HER-2 negative breast cancer, according to phase 2b results released at the joint 15th European Cancer Organization (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress.
More... (http://www.medicalnewstoday.com/articles/165575.php)
More... (http://www.medicalnewstoday.com/articles/165575.php)